WHO COLLABORATING CENTRE FOR INT DRUG MONITORING

The WHO Collaborating Centre for International Drug Monitoring is a specialized entity focused on global pharmacovigilance and drug safety surveillance. Its core capabilities center on the systematic collection, analysis, and dissemination of adverse drug reaction data using standardized methodologies endorsed by the World Health Organization. The organization applies advanced epidemiological and statistical techniques to detect drug safety signals, support risk-benefit assessments, and inform regulatory decision-making across international health systems. Key differentiators include its role as a global hub for the WHO Programme for International Drug Monitoring, its use of the MedDRA terminology, and its contribution to the global database of adverse event reports, enabling real-time monitoring of drug safety trends across diverse populations and healthcare settings. Award history is not available to infer specific agency relationships or contracting patterns. Consequently, no definitive agency experience can be documented based on provided data. The primary NAICS code 513130 corresponds to libraries and archives, which in this context reflects the organization’s function as a custodian and curator of global pharmacovigilance data rather than traditional library services. Its industry focus lies in public health informatics, pharmacovigilance infrastructure, and international health data collaboration, positioning it as a non-commercial, mission-driven entity supporting global drug safety standards rather than a commercial contractor in the traditional sense. The entity is structured as a collaborating centre under the World Health Organization, operating as a non-profit, non-governmental technical unit based in Uppsala, Sweden. It holds no government certifications but derives authority through WHO designation and international scientific consensus. Its geographic presence is global in impact, with data contributions and partnerships spanning over 100 countries, though its operational base remains in Sweden. It functions as a critical node in the international drug safety network rather than as a conventional federal contractor.